AIDS.gov blogs mHealth Summit update This post by AIDS.gov blog provides an update on the second time of the mHealth Summit taking place in Washington, D.C. The meeting aims to advance collaboration in the usage of wireless technology to boost wellness outcomes in the usa and abroad, based on the blog. This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an independent news service editorially, is a program of the Kaiser Family members Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente.Flaherty, M.D., Igor Puzanov, M.D., Kevin B. Kim, M.D., Antoni Ribas, M.D., Grant A. McArthur, M.B., B.S., Ph.D., Jeffrey A. Sosman, M.D., Peter J. O’Dwyer, M.D., Richard J. Lee, M.D., Ph.D., Joseph F. Grippo, Ph.D., Keith Nolop, M.D., and Paul B. Chapman, M.D.: Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Metastatic melanoma is an aggressive disease that there are few effective therapies. Both therapies authorized by the Medication and Food Administration, high-dose interleukin-2 and dacarbazine, are each connected with response prices of only 10 to 20 percent and a small %age of total responses; neither is thought to improve general survival.1,2 In randomized trials, the median survival among patients treated with dacarbazine was significantly less than 8 months.